Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Advertisements

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Figure 1 Lymphocytes during the disease

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Figure 3 The adaptive and maladaptive energy matrices

Figure 3 Connexins in cartilage

Figure 1 Historical evolution of the clinical classification and

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Neurol. doi: /nrneurol

Understanding Biologics

Figure 1 Grip strength across the lifecourse

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Biosimilars in the Real World

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Biosimilars in RA: A Blessing or a Curse?

Figure 4 Ex vivo synovial tissue culture viability

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 1 Biosimilar development process

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 1 Location of HLA variants known to be associated

Figure 3 Endogenous repair of double-strand DNA breaks

Figure 2 Switching of biologic agents and biosimilars

Figure 4 Post-test probability as a function of pre-test

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The two-compartment model of body composition

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 3 Cell-surface markers for NP cell differentiation

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Bone marrow lesions in osteoarthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Research advances in osteoarthritis management

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of biosimilar product development

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Role of TGFβ in a normal and an osteoarthritic joint

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Figure 6 Metabolism of pterins

Figure 1 Principles for the diagnosis and management of osteoarthritis

Figure 1 Transmission of pain by NGF

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Phenotypes of osteoarthritis

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Figure 1 Differential effects of bone-forming agents on bone surfaces

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.79 Figure 1 Clinical trials are needed to explore the effects of switching repeatedly between a bio-originator and its biosimilar or between multiple biosimilars Figure 1 | Clinical trials are needed to explore the effects of switching repeatedly between a bio-originator and its biosimilar or between multiple biosimilars. The NOR-SWITCH study evaluated the transition from infliximab to its biosimilar CT‑P13. Kay, J. & Winthrop, K. L. (2017) Biosimilar switching — “To set a form upon desired change” Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.79